{"id":24063,"date":"2025-07-22T17:05:08","date_gmt":"2025-07-22T15:05:08","guid":{"rendered":"https:\/\/www.investincotedazur.com\/?p=24063"},"modified":"2025-08-05T09:39:28","modified_gmt":"2025-08-05T07:39:28","slug":"horus-pharma-accelerates-its-international-expansion-across-8-new-countries","status":"publish","type":"post","link":"https:\/\/www.investincotedazur.com\/en\/horus-pharma-accelerates-its-international-expansion-across-8-new-countries\/","title":{"rendered":"Horus Pharma accelerates its international expansion across 8 new countries"},"content":{"rendered":"\n
\n
\n
\"Horus<\/figure>\n<\/div>\n\n\n\n
\n

Expansion into 8 new markets<\/strong>
Horus Pharma<\/a> expands into Tunisia, Lebanon, Qatar, Kuwait, Bahrain, Saudi Arabia, the United Arab Emirates, and Oman, consolidating its presence in a region identified as a strategic growth driver.<\/p>\n\n\n\n

Objective: doubling international revenue share<\/strong>
Currently, 15% of Horus Pharma\u2019s revenue comes from international markets. The company aims to double this figure within three years through a multi-model strategy combining subsidiaries, joint ventures, and distribution agreements. <\/p>\n\n\n\n

Sustained growth and economic recognition<\/strong>
Between 2020 and 2023, Horus Pharma achieved 43% revenue growth, earning recognition among the 400 fastest-growing French companies by Les \u00c9chos\/Statista<\/em>.<\/a> <\/p>\n<\/div>\n<\/div>\n\n\n\n

Headquartered in Nice, Horus Pharma\u2014the second-largest independent ophthalmology laboratory in France and a leading European player\u2014announced in July 2025 a new phase of its international expansion.<\/p>\n\n\n\n

Already present in more than 30 countries, Horus Pharma is accelerating its international growth with distribution agreements covering eight additional markets across North Africa and the Middle East: Tunisia, Lebanon, Qatar, Kuwait, Bahrain, Saudi Arabia, the UAE, and Oman.<\/p>\n\n\n\n

This strategic milestone strengthens the company\u2019s international footprint by positioning the Middle East and North Africa as a key growth region in the years ahead. <\/p>\n\n\n\n

<\/div>\n\n\n\n

Strategic presence in a high-potential region<\/strong><\/h2>\n\n\n\n

Through these distribution agreements, Horus Pharma continues to expand market penetration, supported by its participation in the #ETIncelles program since 2023<\/a>. The ophthalmology market in the Middle East and North Africa is rapidly expanding. Valued at USD 3 billion in 2024, it is expected to reach USD 4.5 billion by 2032, with major contributions from Saudi Arabia, the UAE, Israel, and Turkey\u2014markets where Horus Pharma is already active (Digital Bridge Market, 2024). <\/p>\n\n\n\n

Growth is driven by several factors<\/strong>: population aging, rising prevalence of eye diseases (cataract, glaucoma, AMD, diabetic retinopathy), and the rapid adoption of new medical technologies such as OCT, artificial intelligence, and telemedicine.<\/p>\n\n\n\n

To grow in the region, Horus Pharma aims to promote French expertise in ophthalmology while delivering innovative solutions tailored to local healthcare needs.<\/p>\n\n\n\n

\u201cWith these new partnerships, we are now established in nine Middle Eastern countries. This marks a key milestone in our internationalization strategy. This diverse, fast-growing region represents a major growth driver where we want to showcase French excellence in eye health. More broadly, exports remain an essential growth lever for Horus Pharma.\u201d \u2014 Nicolas Claret, International Director, Horus Pharma<\/em><\/strong><\/p><\/blockquote>\n\n\n\n

<\/div>\n\n\n\n

An agile and ambitious international strategy<\/strong><\/h2>\n\n\n\n

With 15% of revenue currently generated outside France, Horus Pharma is making international expansion a strategic growth driver. The company aims to double this share within three years, thanks to a long-term strategy based on agility and strong local proximity.
The laboratory combines several growth levers: subsidiaries, targeted joint ventures, and carefully selected distribution agreements, ensuring market approaches adapted to the economic, regulatory, and cultural realities of each territory. <\/p>\n\n\n\n

This multi-model approach has already secured strong positions in Europe (notably Spain, Benelux, Switzerland, the Nordics, Monaco, and Romania<\/a>) while expanding distribution across more than 30 countries in Europe, North Africa, and now the Middle East.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Promoting French excellence in eye health<\/strong><\/h2>\n\n\n\n

With a portfolio of 70 products <\/strong>covering the full spectrum of eye care needs\u2014from common to rare conditions, including pharmaceuticals, medical devices, human tissue, dermo-cosmetics, and nutritional supplements\u2014Horus Pharma continues to leverage the global recognition of French scientific rigor and industrial quality.<\/p>\n\n\n\n

This international trajectory<\/strong> builds on sustained growth: the company recorded a 43% revenue increase between 2020 and 2023<\/strong>, earning a place in the Les \u00c9chos\/Statista ranking of France\u2019s 400 fastest-growing companies. In 2024, Horus Pharma and its 250 employees achieved \u20ac107M in revenue (+14%).<\/strong><\/p>\n\n\n\n